Section 03 — The Lab Evidence
Oath Research lab evidence: what the testing record actually shows.
Is Oath Research legit on the testing-evidence layer? The testing program at the centre of the legitimacy assessment — Freedom Diagnostics CLIA-certified independent third-party lab, 199 batches tested, 99.60% average purity, USP <85> endotoxin standard, every batch publicly searchable.
Section 03.1 — Why It Matters
Why testing evidence is the central legitimacy proof
Is Oath Research legit on the testing-evidence layer? Yes — the layer where the assessment is most decisively established. The scam-vendor pattern in research peptides is almost always built around a testing-evidence absence. The strong signal of legitimacy is verifiable: a named third-party laboratory whose credentials resolve in an independent database, a public batch-searchable COA archive, and recent test dates. Oath has all three.
Is Oath Research third-party tested?
Yes. Every batch is tested by Freedom Diagnostics, an independent CLIA-certified third-party laboratory in Franklin, Tennessee. 199 batches tested as of May 2026 with 99.60% average purity. Testing is batch-level — not lot-level and not spot-check — so every shipped unit maps to its own COA. This is a stronger commitment than the industry default, which generally tests by lot or by sample.
What lab does Oath Research use?
Freedom Diagnostics — independent commercial laboratory in Franklin, Tennessee, CLIA 14D2263999. Public website at freedomdiagnosticstesting.com, operating since approximately 2023, serving multiple unrelated peptide vendors. Third-party testing only — no ownership or affiliation. Multiple unrelated client vendors mean the lab’s reputation does not depend on Oath, and Oath does not control the laboratory’s certification standing.
Section 03.2 — The Lab
Who is Freedom Diagnostics?
Freedom Diagnostics is a real, separately operated, federally CLIA-registered commercial laboratory. It operates a public website at freedomdiagnosticstesting.com, is based in Franklin TN, specializes in high-precision purity testing for research-use peptides, has been operating since approximately 2023, and serves multiple unrelated peptide vendors. CLIA 14D2263999 resolves in the federal CMS database to a verifiable entity meeting federal-standard laboratory testing requirements.
The disposition against any “fake lab” framing is direct: a phantom laboratory would have to manufacture a public website, fabricate a CLIA number that survives federal-database lookup, and maintain consistent batch attribution across 199 records. None of those is possible against an actually-issued federal certification.
What is CLIA certification and why does it matter?
Clinical Laboratory Improvement Amendments — a federal certification program administered by CMS. CLIA-certified labs are subject to federal oversight, inspection, and proficiency testing. The certification is meaningful because it is structural: a vendor cannot self-assert it, and a phantom laboratory cannot acquire a CLIA registration that survives federal-database lookup. CLIA is a legitimacy hurdle that algorithmic trust-scoring services do not check — those rely on metadata heuristics (WHOIS, SSL, domain age) rather than regulatory certifications.
How many batches has Oath Research tested?
199 batches as of May 2026, and the archive is actively growing. Each batch maps to a publicly searchable COA at oathresearch.com/lab-results-certificates. The independent third-party reviewer RealPeptidesScores has audited 142 of those 199 COAs — a 57-COA shortfall (~29%), meaning the third-party listing is conservative rather than inflated. A third-party reviewer that audits fewer records than the vendor publishes is the inverse of the scam pattern (in which third-party listings inflate beyond the vendor’s actual archive).
What is Oath Research’s average purity?
99.60% portfolio average. Per-compound, from the public COA archive at the May 2026 snapshot:
| Compound | Latest Purity | Batches | Latest Test | Endotoxin |
|---|---|---|---|---|
| BPC-157 | 99.66% | 10 | 2026-05 | PASSED |
| SS-31 | 99.86% | 4 | 2026-05 | PASSED |
| Selank | 99.71% | 5 | 2026-05 | PASSED |
| GLP2-T (Tirzepatide) | 99.93% | 8 | 2026-05 | PASSED |
| Tesamorelin + Ipamorelin | 99.43% | 6 | 2026-05 | PASSED |
| WOLVERINE (BPC-157 + TB-500) | 99.39% | 8 | 2026-05 | PASSED |
The spread across compound classes — GLP-1 agonists, mitochondrial-targeted, recovery, nootropic, and multi-peptide blends — demonstrates that the purity record holds across categories rather than being concentrated in a single hero compound. Blends deserve weight because blend testing is operationally harder than monomer testing: the laboratory must verify the ratio of two or more compounds. Sustaining 99.39% on the WOLVERINE blend across 8 batches is a transparency signal scam operations would not invest in.
Does Oath Research publish COAs?
Yes. The archive at oathresearch.com/lab-results-certificates is publicly accessible (no paywall, no login) and searchable by peptide name, batch number, or CAS number. Each COA shows purity %, endotoxin pass/fail (USP <85>), test date, lab partner. 199 COAs visible as of May 2026; the most recent test dates are also May 2026 — the program is active, not a one-time photo op.
Can I trust Oath Research’s COAs?
The structural trust signals are present: each COA names a real CLIA-certified third-party laboratory, is publicly searchable by batch number, shows the testing method (HPLC purity, USP <85> endotoxin), and carries recent test dates. Verifiability is the trust mechanism, not vendor self-attestation.
The empirical confirmation is also in the public record. Customer Nancy I. (oath.reviews, 2026-05-23): “Sent my own sample of their tirzepatide for an independent test and it lined up with the posted COA.” Donna J. reports a habitual practice: “I check posted COAs against the lot numbers every order and Oath has never been off.” Multiple other reviewers report QR-scan-to-HPLC verification. Customer-conducted independent verification of a published COA is the strongest possible test, and in Nancy I.’s case the test passed. Independently Corroborated